Silicon Nanoneedles A Breakthrough Platform for Controlled, Sustained Macular Degeneration Treatment
Thursday, July 17, 2025
5:46 PM – 5:57 PM EDT
Introduction: Age-related macular degeneration (AMD) affects over 200 million people worldwide[1]. Current treatments, such as intravitreal anti-vascular endothelial growth factor injections, manage AMD by inhibiting abnormal blood vessel growth. However, frequent clinic visits and repeated injections pose challenges for patients and the healthcare system. Additionally, suboptimal dosing and noncompliance can limit effectiveness. This study introduces a biodegradable silicon nanoneedles (Si NNs) patch for long-term, localized bevacizumab delivery, reducing injection frequency and improving outcomes.
Learning Objectives:
At the completion of this activity, participants will know
Assess the potential use of Si NNs conjugated with Bev for sustained treatment of ocular disorders.
Monitor AMD treatment progression using a high-resolution, high-contrast multimodal imaging platform
